Status:
ACTIVE_NOT_RECRUITING
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
Lead Sponsor:
Bispebjerg Hospital
Collaborating Sponsors:
Amager Hospital
University Hospital Bispebjerg and Frederiksberg
Conditions:
Acute Myocardial Infarction
Non-ST Elevation Myocardial Infarction (nSTEMI)
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, ...
Detailed Description
Aim: To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of recurrent MI, all-ca...
Eligibility Criteria
Inclusion
- Left ventricular ejection fraction \> 40%
- Myocardial infarction (MI) within previous two weeks
- The diagnosis of acute MI must meet the Universal European Society of Cardiology (ESC) definition of MI
Exclusion
- Clinical evidence of heart failure at the time of discharge
- Pregnancy or of child bearing age not using safe anticonception throughout the study period
- Lack of signed informed consent and expected cooperation during follow-up
- Any medical condition where beta blocker treatment is indicated according to the treating physician
Key Trial Info
Start Date :
December 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 10 2035
Estimated Enrollment :
2760 Patients enrolled
Trial Details
Trial ID
NCT03778554
Start Date
December 17 2018
End Date
December 10 2035
Last Update
June 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23
Copenhagen, Denmark, 2400